UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Breast (Edinburgh), 2024-08, Vol.76, p.103761, Article 103761

2024

Volltextzugriff (PDF)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Therapeutic Advances in Medical Oncology, 2021-11, Vol.13, p.17588359211059587

2021

Volltextzugriff (PDF)

Effects of binge drinking during adolescence and emerging adulthood on the brain: A systematic review of neuroimaging studies

Neuroscience and biobehavioral reviews, 2022-06, Vol.137, p.104637-104637, Article 104637

2022

Volltextzugriff (PDF)

Enhancing global access to cancer medicines

CA: a cancer journal for clinicians, 2020-03, Vol.70 (2), p.105-124

2020

Volltextzugriff (PDF)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.133-133, Article 133

2019

Volltextzugriff (PDF)

Clinicopathological and molecular predictors of 18FFDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

European journal of nuclear medicine and molecular imaging, 2024-07, Vol.51 (9), p.2733

2024

Volltextzugriff (PDF)

La distribución social de la tierra en el Bajo Miño (1600-1850), ¿Es posible el excedente campesino en comunidades minifundistas?

Cuadernos de estudios gallegos, 2010-12, Vol.57 (123), p.299-318

Pérez García, José Manuel

2010

Volltextzugriff (PDF)

Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-12-07-OT1-12-07

2022

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

The Lancet (British edition), 2024-04, Vol.403 (10437), p.1649

2024

Volltextzugriff (PDF)

Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13632-e13632

2023

Volltextzugriff (PDF)

Abstract P5-13-30: Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-30

2022

Volltextzugriff (PDF)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Breast cancer research : BCR, 2020-01, Vol.22 (1), p.9-9, Article 9

2020

Volltextzugriff (PDF)

Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1084-1084

2022

Volltextzugriff (PDF)

Abstract P5-16-12: Neoadjuvant letrozole plus palbociclib in patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) with baseline Ki67 ≥20% and an Oncotype DX Breast Recurrence Score® result (RS) ≥18: DxCARTES

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-16-12

2022

Volltextzugriff (PDF)

Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD4-06-PD4-06

2022

Volltextzugriff (PDF)

Abstract PO5-16-12: EFFICACY AND TOLERABILITY OF METRONOMIC CHEMOTHERAPY (mChT) WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND CAPECITABINE (CMX) IN PATIENTS WITH HEAVILY PRETREATED ADVANCED BREAST CANCER. RESULTS FROM A MULTICENTER RETROSPECTIVE STUDY

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO5-16-12-PO5-16-12

2024

Volltextzugriff (PDF)

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-19-06-OT2-19-06

2022

Volltextzugriff (PDF)

1 – 25 von 5.158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.299)
Mit Volltextzugriff
(4.477)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.890)
Life Sciences & Biomedicine
(2.460)
Humans
(1.776)
Female
(1.140)
Male
(1.063)
Middle Aged
(791)
Aged
(691)
Adult
(636)
Spain
(371)
Risk Factors
(362)
Patients
(319)
Aged, 80 And Over
(302)
Spain - Epidemiology
(294)
Prospective Studies
(293)
General & Internal Medicine
(287)
Mortality
(279)
Infectious Diseases
(272)
Cardiovascular System & Cardiology
(268)
Technology
(261)
Medicine, General & Internal
(248)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(2.985)
Ingenta E-Journals
(2.196)
MEDLINE
(1.945)
Elsevier ScienceDirect Journals Complete
(1.222)
Journals@Ovid Full Text
(1.077)
IngentaConnect Journals
(941)
Publisher or Other Site
(546)
Springer Online Journals
(436)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(384)
Wiley Online Library
(382)
Wiley Online Library Full Collection 2018
(279)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(221)
eBooks on EBSCOhost
(201)
Ebook Central Perpetual and DDA
(200)
Oxford journals
(185)
Oxford Journals 2020 Medicine
(154)
Nature
(115)
Taylor & Francis Journals
(84)
SpringerLink Series
(80)
IEEE Xplore
(78)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial

Effects of binge drinking during adolescence and emerging adulthood on the brain: A systematic review of neuroimaging studies

Enhancing global access to cancer medicines

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Clinicopathological and molecular predictors of 18FFDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

La distribución social de la tierra en el Bajo Miño (1600-1850), ¿Es posible el excedente campesino en comunidades minifundistas?

Abstract OT1-12-07: A phase 2 study of chemotherapy de-escalation using a pathological response-guided strategy in patients with HER2-positive, low-risk early breast cancer: PHERGain-2

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)

3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Clinical utility of a novel non-invasive technology for monitoring severe neutropenia in anticancer therapy

Abstract P5-13-30: Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)

Abstract P5-16-12: Neoadjuvant letrozole plus palbociclib in patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) with baseline Ki67 ≥20% and an Oncotype DX Breast Recurrence Score® result (RS) ≥18: DxCARTES

Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study

Abstract PO5-16-12: EFFICACY AND TOLERABILITY OF METRONOMIC CHEMOTHERAPY (mChT) WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND CAPECITABINE (CMX) IN PATIENTS WITH HEAVILY PRETREATED ADVANCED BREAST CANCER. RESULTS FROM A MULTICENTER RETROSPECTIVE STUDY

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Suchergebnisse filtern